Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin Nebulization and Hospital Stay in Acute COPD Exacerbation
TCTR20260105001Recruiting
- Sponsor
- Navamindradhiraj University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of revefenacin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Navamindradhiraj University. Primary endpoint: Length of hospital stay. Started Jan 2025; status: recruiting.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on TCTR20260105001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260105001.